EP4171539A4 - Zusammensetzungen und verfahren zur behandlung von morbus alzheimer und morbus parkinson - Google Patents

Zusammensetzungen und verfahren zur behandlung von morbus alzheimer und morbus parkinson Download PDF

Info

Publication number
EP4171539A4
EP4171539A4 EP20942038.9A EP20942038A EP4171539A4 EP 4171539 A4 EP4171539 A4 EP 4171539A4 EP 20942038 A EP20942038 A EP 20942038A EP 4171539 A4 EP4171539 A4 EP 4171539A4
Authority
EP
European Patent Office
Prior art keywords
disease
parkinson
compositions
methods
treating alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20942038.9A
Other languages
English (en)
French (fr)
Other versions
EP4171539A1 (de
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA PharmaTech Inc
Original Assignee
LA PharmaTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA PharmaTech Inc filed Critical LA PharmaTech Inc
Publication of EP4171539A1 publication Critical patent/EP4171539A1/de
Publication of EP4171539A4 publication Critical patent/EP4171539A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20942038.9A 2020-06-26 2020-06-26 Zusammensetzungen und verfahren zur behandlung von morbus alzheimer und morbus parkinson Pending EP4171539A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/039916 WO2021262196A1 (en) 2020-06-26 2020-06-26 Compositions and methods for treating alzheimer's disease and parkinson's disease

Publications (2)

Publication Number Publication Date
EP4171539A1 EP4171539A1 (de) 2023-05-03
EP4171539A4 true EP4171539A4 (de) 2024-01-17

Family

ID=79281652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20942038.9A Pending EP4171539A4 (de) 2020-06-26 2020-06-26 Zusammensetzungen und verfahren zur behandlung von morbus alzheimer und morbus parkinson

Country Status (5)

Country Link
EP (1) EP4171539A4 (de)
JP (1) JP2023539405A (de)
CN (1) CN115776885A (de)
CA (1) CA3183560A1 (de)
WO (1) WO2021262196A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010260808A (ja) * 2009-05-01 2010-11-18 Ikeda Mohando:Kk 肌状態改善用経口医薬組成物
US20190030061A1 (en) * 2016-03-01 2019-01-31 Nova Southeastern University Cobalamin compositions and use thereof for improving cognitive function
US10639314B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP5607291B2 (ja) * 2004-11-24 2014-10-15 メダ ファーマシューティカルズ インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2007030108A1 (en) * 2005-09-07 2007-03-15 Bebaas, Inc. Vitamin b-12 compositions
WO2007061454A1 (en) * 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
CN101134048B (zh) * 2007-05-31 2010-11-10 复旦大学附属中山医院 一种预防和治疗阿尔茨海默病与衰老的药物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010260808A (ja) * 2009-05-01 2010-11-18 Ikeda Mohando:Kk 肌状態改善用経口医薬組成物
US20190030061A1 (en) * 2016-03-01 2019-01-31 Nova Southeastern University Cobalamin compositions and use thereof for improving cognitive function
US10639314B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10639316B1 (en) * 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Parkinson's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
See also references of WO2021262196A1 *

Also Published As

Publication number Publication date
EP4171539A1 (de) 2023-05-03
JP2023539405A (ja) 2023-09-14
WO2021262196A1 (en) 2021-12-30
CA3183560A1 (en) 2021-12-30
CN115776885A (zh) 2023-03-10

Similar Documents

Publication Publication Date Title
EP4171539A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus alzheimer und morbus parkinson
EP4146229A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus pompe
EP4196113A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson
EP3927710A4 (de) Zusammensetzungen und verfahren zur behandlung oder prävention von morbus alzheimer
EP3990018A4 (de) Verfahren und zusammensetzungen zur behandlung von morbus alzheimer
EP4415755A4 (de) Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19
EP4228616A4 (de) Zusammensetzungen und verfahren zur behandlung von schilddrüsenaugenkrankheit
EP4370672A4 (de) Genomeditierungszusammensetzungen und verfahren zur behandlung der wilson-krankheit
EP4221719A4 (de) Zusammensetzungen und verfahren zur behandlung von angiopoietin-like 7 (angptl7)-bedingten erkrankungen
EP4188368A4 (de) Zusammensetzungen und verfahren zur behandlung von erkrankungen und störungen
EP4096439A4 (de) Zusammensetzungen und verfahren zur behandlung von altersbedingten erkrankungen
EP3986439A4 (de) Zusammensetzungen und verfahren zur behandlung von hirnerkrankungen
EP4329763A4 (de) Verfahren zur behandlung und überwachung von morbus parkinson
EP4277988A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus fabry
EP4408412A4 (de) Zusammensetzungen und verfahren zur behandlung von kopfschmerzen
EP3684388A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus huntington
EP4460525A4 (de) Zusammensetzungen und verfahren zur behandlung von schilddrüsenaugenkrankheit
EP4097236A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
EP4518846A4 (de) Zusammensetzungen und verfahren zur behandlung von epilepsie
EP4433076A4 (de) Zusammensetzungen und verfahren zur behandlung von augenerkrankungen und -verletzungen
EP4028038A4 (de) Peptidbasierte zusammensetzungen und verfahren zur behandlung von morbus alzheimer
EP4271420A4 (de) Verfahren und zusammensetzungen zur behandlung von friedreich-ataxie
EP4025199A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus alzheimer
EP4340860A4 (de) Zusammensetzungen und verfahren zur behandlung von neuropathie
EP4376824A4 (de) Zusammensetzungen und verfahren zur behandlung von morbus alzheimer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20231214BHEP

Ipc: A61P 25/14 20060101ALI20231214BHEP

Ipc: A61K 9/24 20060101ALI20231214BHEP

Ipc: A61K 9/20 20060101ALI20231214BHEP

Ipc: A61K 31/192 20060101AFI20231214BHEP